

**RoL nr 245 december 2023**

## **Referenser**

### **Spontanrapportering av biverkningar – ett essentiellt verktyg i jakten på okända säkerhetsproblem**

<https://www.lakemedelsverket.se/sv/rapportera-biverkningar/lakemedel/misstankt-biverkning-hos-manniska>

<https://www.ema.europa.eu/en/human-regulatory/overview/pharmacovigilance-overview>

<https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/signal-management>

[https://www.ema.europa.eu/en/documents/other/questions-answers-signal-management\\_en.pdf](https://www.ema.europa.eu/en/documents/other/questions-answers-signal-management_en.pdf)

### **Opioider och obesitaskirurgi, del 2**

1. Wallén S, Bruze G, Ottosson J, Marcus C, Sundström J, Szabo E, et al. Opioid Use After Gastric Bypass, Sleeve Gastrectomy or Intensive Lifestyle Intervention. *Ann Surg.* 2023;277(3):e552-e60.
2. Hachon L, Reis R, Labat L, Poitou C, Jacob A, Declèves X, et al. Morphine and metabolites plasma levels after administration of sustained release morphine in Roux-en-Y gastric bypass subjects versus matched control subjects. *Surg Obes Relat Dis.* 2017;13(11):1869-74.
3. Lloret-Linares C, Hirt D, Bardin C, Bouillot JL, Oppert JM, Poitou C, et al. Effect of a Roux-en-Y gastric bypass on the pharmacokinetics of oral morphine using a population approach. *Clin Pharmacokinet.* 2014;53(10):919-30.
4. Ladebo L, Abuhelwa AY, Foster DJR, Kroustrup JP, Pacyk GJ, Kongstad KT, et al. Effect of Roux-en-Y gastric bypass on the pharmacokinetic-pharmacodynamic relationships of liquid and controlled-release formulations of oxycodone. *Basic Clin Pharmacol Toxicol.* 2021;129(3):232-45.
5. Acevedo MB, Eagon JC, Bartholow BD, Klein S, Bucholz KK, Pepino MY. Sleeve gastrectomy surgery: when 2 alcoholic drinks are converted to 4. *Surg Obes Relat Dis.* 2018;14(3):277-83.